Company
Convexia
An end-to-end AI stack that replaces months of manual diligence with fast execution.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- pharma, biotech, and investment groups
Claim, correct or request removal
Record updated 17 September 2026
About
Our long-term goal is to operate the full drug lifecycle ourselves — acquiring assets, running clinical trials, and selling them to strategic buyers. As a first step, we are licensing components of our platform and running pilots with pharma, biotech, and investment groups to demonstrate value and build traction.
Loading relationship preview